In the current study, we investigated the anti-tumor efficacy of XAV939 and a novel nitro-substituted derivative (WXL-8), in both in vitro and in vivo models of HCC, and demonstrated that tankyrase inhibition is a feasible approach in the treatment of HCC. Here, TNKS is linked to neoplasm.